Ipsen SA Price, Chart & Factor Exposure
Free Data & Analytics AccessNext earnings: Thu, Feb 11, 2027, after the market closes · estimates and history
Ipsen SA Forecast
Ipsen SA short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is positive (5 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 21.6% a year, a typical one-standard-deviation range is 150.66–160.14 over a week, 145.69–165.11 over a month and 121.78–189.02 over a year. (Signals as of 5 Nov 2026.)
Ipsen SA Price Chart
Ipsen SA Factors
YoY +42.8%
YoY +10.3%
YoY +9.0%
YoY −8.8%
YoY +6.6%
YoY +6.4%
YoY −30.0%
YoY —
YoY +21.4%
YoY +108.4%
YoY +62.1%
YoY −0.9%
YoY +2.5%
YoY −12.2%
YoY −10.1%
YoY +25.0%
YoY +10.8%
Ipsen SA fundamentals: income statement, balance sheet & cash flow
Ipsen SA reported revenue of €3.68bn and net income of €444.5m in FY2025, the year ended 31 December 2025 — revenue up 2.8% and net income up 28.5% on the prior year. Free cash flow was €1.03bn. These figures are as reported in the filings, not restated: 24 fiscal years and 84 quarters of history, back to December 2002.
| EUR millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 3,675.9 | 3,574.5 | 3,306.4 | 3,156.4 | 2,748.6 |
| Cost of revenue | 1,081.3 | 618.7 | 571.2 | 527.7 | 438.6 |
| Gross profit | 2,594.6 | 2,955.8 | 2,735.2 | 2,628.7 | 2,310.0 |
| Research & development | 754.0 | 686.6 | 619.3 | 445.3 | 424.4 |
| Selling, general & admin. | 1,094.3 | 1,772.5 | 1,299.9 | — | — |
| Operating income | 746.3 | 496.7 | 816.0 | 943.7 | 886.2 |
| EBITDA | 1,102.6 | 1,161.3 | 1,157.6 | 1,145.0 | 1,059.2 |
| Interest expense | 36.1 | 23.8 | 19.4 | 23.8 | 23.7 |
| Pre-tax income | 578.2 | 432.2 | 756.1 | 704.4 | 789.5 |
| Income tax | 133.6 | 74.9 | 136.2 | 112.3 | 158.3 |
| Net income | 444.5 | 345.9 | 644.4 | 648.6 | 646.6 |
Download Ipsen SA fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.IPN.PA&statement=all&freq=a&format=csv&years=10
Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on Ipsen SA
Explore MacroFinance macro & markets research and analysis.
Ipsen SA Trading Strategies
9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Ipsen SA; 1 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in VGK | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Defensive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation - CPR | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's Optimum3 | Moderate | Monthly | Premium · upgrade to view | |||
| Wouter Keller's Bold Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Vigilant Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Ilya Kipnis' Defensive Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keuning and Keller's Generalized Protective Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Ipsen SA’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Ipsen SA (France)
Ipsen SA is a listed security in France. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Ipsen SA?
What is the latest Ipsen SA price?
Is Ipsen SA in an uptrend?
How volatile is Ipsen SA?
What factors affect Ipsen SA?
Which trading strategies trade Ipsen SA?
How are Ipsen SA returns analysed?
Where can I download free Ipsen SA historical data?
Free Ipsen SA historical data (last 10 years)
Browse or instantly download the last 10 years of Ipsen SA daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.IPN.PA&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 161.6 |
| 2026-11-19 | 162.4 |
| 2026-11-18 | 163 |
| 2026-11-17 | 164.1 |
| 2026-11-16 | 167.4 |
| 2026-11-13 | 166.4 |
| 2026-11-12 | 167 |
| 2026-11-11 | 167.3 |
| 2026-11-10 | 166 |
| 2026-11-09 | 163.4 |
About this stock
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.